 arb stori us downgrad
messag downgrad buy neutral sinc
increasingli view merger expect close
continu primari driver stock current spread agn current
price impli acquisit price materi
upsid catalyst sharehold expect close
transact downgrad stock neutral remov price
target result previou price target
downgrad buy neutral earlier cs
announc propos acquisit cash
share share believ remain opportun
sharehold arbitrag opportun base current trade price agn
impli acquisit price wake
today solid spectacular result earn guidanc weigh
increas charg relat textur breast implant recal well increas sg
spend gear sustain global aesthet busi growth see potenti upsid
sharehold depend almost exclus perform share
sinc guggenheim publish fundament view combin
abbv/ newco longer recommend purchas basi
captur spread close transact
stand-alone model still includ zenpep brazikumab plan
sell estim two product could worth
outright sale approxim zenpep sale brazicumab peak risk-adjust
sale discount back agn/abbv agre expedi close
transact import possibl brazikumab right could revert azn sinc
conting payment associ mileston could limit interest drug rel
overal valu transact view plan sale zenpep brazicumab
larg inconsequenti sharehold although like import time
close deal
page analyst certif import disclosur
view reflect plan acquisit assum follow
sustain leadership medic aesthet botox juvederm coolsculpt
sustain double-digit growth vraylar
long-term pipelin option relamorelin novel agent diabet gastroparesi
impli valuat vs previous assum transact close receiv
share cash share per share impli price base close price
guggenheim research publish fundament view
stand-alone basi see fair valu base blend dcf analysi valu
base sale wacc consist discount rate use global pharma co
termin growth vs global pharma reflect cost agn open scienc strategi base case sum part
analysi sotp valu unchang
failur close acquisit
botox use declin due cgrp mab faster anticip
clinic failur atogep and/or relamorelin
strong continu perform botox vraylar juvederm
overal improv margin
page analyst certif import disclosur
usd million except ep
compani report guggenheim secur llc estim
page analyst certif import disclosur
